AVI BioPharma (AVII -15.4%) tanks after it says the U.S. Department of Defense told the company...


AVI BioPharma (AVII -15.4%) tanks after it says the U.S. Department of Defense told the company its proposal for the full clinical development of its influenza drug candidate, AVI-7100, didn't qualify for a contract award.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs